Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$40.88 USD

40.88
10,230,845

-0.36 (-0.87%)

Updated Jun 6, 2024 04:00 PM ET

After-Market: $40.83 -0.05 (-0.12%) 6:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Indrajit Bandyopadhyay headshot

Bristol-Myers (BMY) Q2 Earnings Beats Estimates

by Indrajit Bandyopadhyay

Bristol-Myers (BMY) reports second-quarter results beating both earnings and sales estimates.

    AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?

    by Zacks Equity Research

    AVEO Pharmaceuticals (AVEO) depends on collaboration revenues and milestone and other payments for its top line. The CHMP recommendation for tivozanib MAA received during the quarter was a positive.

      Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN

      by Zacks Equity Research

      Bristol-Myers Squibb Company (BMY), Celgene (CELG) and Alexion Pharma (ALXN) are set to report second-quarter results on Jul 27.

        What's in the Cards for Exelixis (EXEL) in Q2 Earnings?

        by Zacks Equity Research

        Exelixis, Inc.'s (EXEL) efforts to develop its pipeline and uptake in Cabometyx sales should be the key areas of focus when the company reports second-quarter results.

          Sweta Killa headshot

          Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs

          by Sweta Killa

          Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.

            What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings?

            by Zacks Equity Research

            Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%.

              Arpita Dutt headshot

              Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

              by Arpita Dutt

              Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

                Gilead's HCV Portfolio Receives a Boost With Vosevi Approval

                by Zacks Equity Research

                Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.

                  Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?

                  by Zacks Equity Research

                  Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company's shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period.

                    Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx

                    by Zacks Equity Research

                    Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.

                      Bristol-Myers Gets FDA Nod for Orencia's Label Expansion

                      by Zacks Equity Research

                      Bristol-Myers Squibb Company (BMY) announced that the FDA has approved Orencia for treatment of adults with active psoriatic arthritis (PsA).

                        Arpita Dutt headshot

                        Pharma Stock Roundup: MRK's Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook

                        by Arpita Dutt

                        3 studies on Merck's (MRK) Keytruda have been put on clinical hold while Bayer said that it expects to revise its 2017 outlook when it reports Q2 results.

                          Bristol-Myers' Opdivo Superior to Yervoy in Melanoma Study

                          by Zacks Equity Research

                          Bristol-Myers Squibb Company (BMY) announced that a phase III study, CheckMate-238, evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg met its primary endpoint at a planned interim analysis.

                            Company News for July 06, 2017

                            by Zacks Equity Research

                            Companies in the News are: ORLY,BMY,MORE,PRPO

                              Gilead's (GILD) HCV Drug Application Accepted in the EU

                              by Zacks Equity Research

                              Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.

                                Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti

                                by Zacks Equity Research

                                Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.

                                  AVEO's Kidney Cancer Candidate Gets CHMP Recommendation

                                  by Zacks Equity Research

                                  AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

                                    by Arpita Dutt

                                    All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

                                      AVEO Reaches Enrollment Target in Pivotal Tivozanib Study

                                      by Zacks Equity Research

                                      AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target

                                        Exelixis's Cabometyx Positive for First-Line Kidney Cancer

                                        by Zacks Equity Research

                                        Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

                                          Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada

                                          by Zacks Equity Research

                                          Health Canada granted a Notice of Compliance (NOC) for Vemlidy 25mg tablets, a once-daily treatment for adults with chronic HBV infection with compensated liver disease.

                                            Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205

                                            by Zacks Equity Research

                                            Bristol-Myers Squibb Company (BMY) announced an extended follow-up data on immuno-oncology drug Opdivo.

                                              J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use

                                              by Zacks Equity Research

                                              Johnson & Johnson (JNJ) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's (CELG) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone.

                                                Arpita Dutt headshot

                                                Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused

                                                by Arpita Dutt

                                                Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.

                                                  Exelixis Initiates Cabozantinib-Tecentriq Combination Trial

                                                  by Zacks Equity Research

                                                  Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.